CELL BANK™

Collection, processing, “long-term” cryopreservation of hematopoietic stem cells from umbilical cord blood for autologous or allogeneic stem cell transplantations.

The procedure consists:

Collection:

Cord blood is being collected from the cord vessels immediately after the delivery and after it’s cut for the neonatal. Normally this blood is being thrown away, so the collection doesn’t affect at all the delivery procedure. The collection is carried out by specialized personnel and the ...

Cord blood is being collected from the cord vessels immediately after the delivery and after it’s cut for the neonatal. Normally this blood is being thrown away, so the collection doesn’t affect at all the delivery procedure. The collection is carried out by specialized personnel and the procedure is the same either in in normal delivery or in cesarean section. Special guidelines are enclosed for the personnel for the cord blood collection, so as they can collect the maximum quantity of blood avoiding the possibility of any contamination. The cord blood is being delivered in special collection KIT that protects it from any possible irradiation, any possible mechanical damages, and furthermore in stable temperature using thermo stable gel packs.

read more

Processing:

The cord blood sample is being coded with a unique barcode for its traceability both during the processing and after the cryopreservation. Sample processing is being carried out immediately upon receive with validated procedures in a completely closed system (biogenea® cryoset). In particular, ...

The cord blood sample is being coded with a unique barcode for its traceability both during the processing and after the cryopreservation. Sample processing is being carried out immediately upon receive with validated procedures in a completely closed system (biogenea® cryoset). In particular, the total nucleated cells (cells with a nucleus, like the progenitor stem cells) are being isolated form the red blood cells and the plasma through sedimentation and centrifugation. The whole procedure is being carried out in a laminar flow class A/B (Annex I - February 2008 EU guideline for the cGMP standards).

read more

Quality Control:

A cell count is being performed both prior to and after the procedure. Prior to the procedure a full blood test is being performed, and the white blood cells, as well as their subgroup are being counted. The blood analysis is carried out using the automated blood analyzer. After the procedure ...

A cell count is being performed both prior to and after the procedure. Prior to the procedure a full blood test is being performed, and the white blood cells, as well as their subgroup are being counted. The blood analysis is carried out using the automated blood analyzer. After the procedure completion, a small amount of the final product is being used for the final numerical counting of the progenitor cells, as well as their viability prior to the cryopreservation using flow cytometry using the ISHAGE (International Society of Hematotherapy and Graft Engineering) protocol. A small amount of the sample is being cryopreserved and thawed especially for a viability test of the progenitor Hematopoietic cells after the cryopreservation procedure. Using this procedure we can guarantee that the viability and the plasticity of the hematopoietic stem cells are intact during the cryopreservation..Adherent cells generated during long-term culture of human umbilical cord blood CD34+ cells have characteristics of endothelial cells and beneficial effect on cord blood ex vivo expansion. Yoo E et.al., Stem Cells 21: 228-235, 2003 A small amount of the plasma is controlled for the presence of aerobic and anaerobic germs using the automated blood culture system, while in parallel the automated genetic analyzer is used for detections of HBsAg, as well as for Hepatitis C, HIV Ι/ΙΙ , Toxoplasma , Syphilis and CMV.

read more

Long term Cryopreservation & Product Release:

Only after the completion of all the quality tests isolated progenitor Hematopoietic cells are stored in temperatures reaching the -196C ( in these conditions all the metabolic procedures are stopped ) and document/certificate of cryopreservation is issued.

What can you do with it:

Because of our patented technology for the ex vivo hematopoietic stem cell expansion up to Total Nucleated Cells (x100 folds) and CD45+dimCD34+ hematopoietic stem cells (x10 folds), the isolated hematopoietic stem cells could be expanded in case of a future therapeutic use. These cellular ...

Because of our patented technology for the ex vivo hematopoietic stem cell expansion up to Total Nucleated Cells (x100 folds) and CD45+dimCD34+ hematopoietic stem cells (x10 folds), the isolated hematopoietic stem cells could be expanded in case of a future therapeutic use. These cellular populations are being used for many years for the treatment of immune diseases as well as a supporting treatment for some cancers.In particular, after specific treatments such as chemotherapy or irradiation (that destroy the immunological system) a blood system reconstruction is needed. New applications are continuously emerge for the progenitor cells. Especially in the regenerative medicine, these cell populations are applied in order to heal tissues and organs. The cord blood progenitor hematopoietic cells have in general more potency capacity for differentiation than the adult stem cells. There is a perspective for the treatment of diabetes, brain damage, neural disorders, Parkinson's disease and multiple sclerosis. Furthermore, heart infraction and seizures could be added to list of treatments. As a result, a life insurance by cryopreserving cord blood hematopoietic stem cells could be a preventing tool for the contemporary medicine.

read more